Disgraceful. That’s the best description of findings that unnecessary and damaging shortages of some cancer drugs have led to relapses among kids fighting cancer at St. Jude Children’s Hospital and elsewhere.
It wasn’t the hospital’s fault. In fact, it was St. Jude that blew the whistle.
The results are shocking. Children get much sicker and suffer from more severe side effects. Sometimes, their cancer returns.
It doesn’t have to be that way. Stronger regulation and oversight of drug supplies, plus better product and inventory management by private drug manufacturers could fix it.
— The Commercial Appeal, Memphis
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less